Medical Genetics · Agammaglobulinemia, Microcephaly, Craniosynostosis, and Severe Dermatitis Syndrome

Genetics, Genetic Testing, and Overlapping Conditions

At a Glance

AMCSS is an unsolved genetic disorder because its causative gene has not been identified. Whole-exome or whole-genome sequencing, testing for DNA-repair mimics, and periodic reanalysis may help, while a negative result or VUS does not establish the diagnosis.

When a child is diagnosed with an ultra-rare condition, one of the first questions parents ask is “Why?” In most cases, the answer lies in the child’s genetic code. However, because this specific syndrome is so rare, the exact gene responsible has not yet been identified ^[1]. This makes it an unsolved genetic disorder, a term used when doctors suspect a condition is genetic but cannot yet name the specific DNA change.

How the Syndrome is Inherited

Based on the original cases, researchers suggested this syndrome may follow an autosomal recessive inheritance pattern ^[1].

The Basics: Every person has two copies of most genes—one from their mother and one from their father. In a known recessive condition, a child must inherit two non-working copies of the same gene to show symptoms.
The Parents: Typically, both parents are carriers. This means they have one working copy and one non-working copy of the gene. Carriers usually have no symptoms and may never know they carry the gene until they have an affected child ^[2]^[3].
The Odds: If a specific recessive gene is established, there is a 25% chance with each pregnancy that the child will be affected. However, because the gene for this condition is unknown, this recurrence risk is only an estimate and is currently uncertain for your family. Direct reproductive decisions to a genetic counselor ^[2]^[3].

Ruling Out the “Mimics”

Because the specific gene is unknown, doctors must first rule out other conditions that look very similar. These “mimics” often involve problems with how the body repairs its own DNA.

DNA Repair Disorders (LIG4 and NHEJ1)

The body has a specialized “repair kit” called non-homologous end joining (NHEJ) that fixes breaks in DNA. This kit is also used to build the immune system’s antibodies ^[4]^[5].

LIG4 Deficiency: This can cause a small head (microcephaly), developmental delays, and a lack of antibodies (agammaglobulinemia) ^[6]^[7].
NHEJ1/Cernunnos-XLF Deficiency: This also leads to microcephaly and immune problems ^[8].
To rule these out, specialized laboratories may selectively use a DNA repair assay or radiosensitivity test. In these tests, a small sample of cells is exposed to a controlled amount of radiation to see if they can repair the damage ^[9]^[10].

ICF2 Syndrome (ZBTB24)

Another mimic is ICF2 syndrome, caused by changes in the ZBTB24 gene ^[11]. Like the Crow phenotype, it causes low antibody levels and facial differences, but it has a unique “signature” in the DNA called hypomethylation that doctors can test for specifically ^[12]^[13].

The Importance of Genomic Testing

Since there is no single test for this condition, doctors use broad searches like Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) ^[14]. These tests scan thousands of genes at once to look for any rare variations. Note that a “Variant of Uncertain Significance” (VUS) might be found; a VUS is a change not fully understood and should not be used as a diagnosis.

If the initial test is negative, it does not mean there is no genetic cause—it just means science hasn’t found it yet. Periodic review with genetics is often recommended. Your team may suggest re-examining your child’s genetic data depending on laboratory policy ^[15]. New disease genes are discovered over time; a “mystery” today may be solved later simply because another family elsewhere in the world was found with the same genetic change ^[16]^[17]. Diagnosing the “unsolved” can eventually help your team better predict your child’s health needs ^[18].

Common questions in this guide

Why is AMCSS called an unsolved genetic disorder?

The gene responsible for agammaglobulinemia, microcephaly, craniosynostosis, and severe dermatitis syndrome has not been identified. Doctors may still believe the condition has a genetic cause, but current testing cannot yet name the responsible DNA change.

What genetic tests may be used when AMCSS is suspected?

Whole-exome sequencing and whole-genome sequencing scan many genes at once for a possible cause. Depending on the findings, specialists may also use DNA-repair or radiosensitivity tests and testing for DNA methylation changes to look for similar conditions.

Can AMCSS be passed down by unaffected parents?

The original cases suggested an autosomal recessive pattern, in which an affected child inherits two non-working copies and parents may be healthy carriers. Because the gene is unknown, the recurrence risk for a particular family is uncertain and should be discussed with a genetic counselor.

Which conditions can mimic AMCSS?

LIG4 deficiency, NHEJ1 or Cernunnos-XLF deficiency, and ICF2 syndrome caused by ZBTB24 changes can have overlapping features. DNA-repair or radiosensitivity testing and evaluation for abnormal DNA hypomethylation may help doctors distinguish these conditions.

What does a variant of uncertain significance mean?

A variant of uncertain significance, or VUS, is a DNA change whose health effect is not yet clear. It should not be used by itself to diagnose AMCSS or make major medical decisions, and its meaning may be updated as evidence grows.

Should genetic testing be repeated after a negative result?

A negative result does not prove that no genetic cause exists, especially when the condition's gene has not been identified. Genetics teams may periodically reanalyze stored data as new genes and evidence become available, depending on the laboratory's policy.

Get notified when new evidence is published on Agammaglobulinemia-microcephaly-craniosynostosis-severe dermatitis syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
A newly recognized, likely autosomal recessive syndrome comprising agammaglobulinemia, microcephaly, craniosynostosis, severe dermatitis, and other features.
Crow YJ, Goodship JA, Wright C, et al.
American journal of medical genetics. Part A 2006; (140(11)):1131-5 doi:10.1002/ajmg.a.31275.
PMID: 16691627
2
Autosomal recessive frameshift variant broadens HECW2-related disease spectrum.
Dehghanzad R, Eshaghkhani Y, Saberi M, et al.
European journal of medical genetics 2025; (77()):105036 doi:10.1016/j.ejmg.2025.105036.
PMID: 40812465
3
Prenatal molecularly supported diagnosis of a fetus with urinary malformation caused by novel compound heterozygous variants in the FAM149B1 gene.
Liu J, Wu Y, Xu S, et al.
Intractable & rare diseases research 2026; (15(3)):260-267 doi:10.5582/irdr.2026.01029.
PMID: 42644010
4
XRCC4 deficiency in human subjects causes a marked neurological phenotype but no overt immunodeficiency.
Guo C, Nakazawa Y, Woodbine L, et al.
The Journal of allergy and clinical immunology 2015; (136(4)):1007-17.
PMID: 26255102
5
Ligase-4 Deficiency Causes Distinctive Immune Abnormalities in Asymptomatic Individuals.
Felgentreff K, Baxi SN, Lee YN, et al.
Journal of clinical immunology 2016; (36(4)):341-53 doi:10.1007/s10875-016-0266-5.
PMID: 27063650
6
Failing to Make Ends Meet: The Broad Clinical Spectrum of DNA Ligase IV Deficiency. Case Series and Review of the Literature.
Staines Boone AT, Chinn IK, Alaez-Versón C, et al.
Frontiers in pediatrics 2018; (6()):426 doi:10.3389/fped.2018.00426.
PMID: 30719430
7
Case Report: Wide Spectrum of Manifestations of Ligase IV Deficiency: Report of 3 Cases.
Castro ACE, Maia R, Batalha S, et al.
Frontiers in immunology 2022; (13()):869728 doi:10.3389/fimmu.2022.869728.
PMID: 35592332
8
Update on DNA-Double Strand Break Repair Defects in Combined Primary Immunodeficiency.
Slatter MA, Gennery AR
Current allergy and asthma reports 2020; (20(10)):57 doi:10.1007/s11882-020-00955-z.
PMID: 32648006
9
Application of a radiosensitivity flow assay in a patient with DNA ligase 4 deficiency.
Buchbinder D, Smith MJ, Kawahara M, et al.
Blood advances 2018; (2(15)):1828-1832 doi:10.1182/bloodadvances.2018016113.
PMID: 30061307
10
XLF/Cernunnos: An important but puzzling participant in the nonhomologous end joining DNA repair pathway.
Menon V, Povirk LF
DNA repair 2017; (58()):29-37 doi:10.1016/j.dnarep.2017.08.003.
PMID: 28846869
11
Progressive Immunodeficiency with Gradual Depletion of B and CD4⁺ T Cells in Immunodeficiency, Centromeric Instability and Facial Anomalies Syndrome 2 (ICF2).
Sogkas G, Dubrowinskaja N, Bergmann AK, et al.
Diseases (Basel, Switzerland) 2019; (7(2)) doi:10.3390/diseases7020034.
PMID: 30987377
12
Structural basis of specific DNA binding by the transcription factor ZBTB24.
Ren R, Hardikar S, Horton JR, et al.
Nucleic acids research 2019; (47(16)):8388-8398 doi:10.1093/nar/gkz557.
PMID: 31226215
13
DNA methylation maintenance at heterochromatin.
Wassing IE, Funabiki H
DNA repair 2026; (167()):103965 doi:10.1016/j.dnarep.2026.103965.
PMID: 42843261
14
Clinical implications of systematic phenotyping and exome sequencing in patients with primary antibody deficiency.
Abolhassani H, Aghamohammadi A, Fang M, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(1)):243-251 doi:10.1038/s41436-018-0012-x.
PMID: 29921932
15
Periodic reanalysis of whole-genome sequencing data enhances the diagnostic advantage over standard clinical genetic testing.
Costain G, Jobling R, Walker S, et al.
European journal of human genetics : EJHG 2018; (26(5)):740-744 doi:10.1038/s41431-018-0114-6.
PMID: 29453418
16
Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses.
Laurie S, Steyaert W, de Boer E, et al.
Nature medicine 2025; (31(2)):478-489 doi:10.1038/s41591-024-03420-w.
PMID: 39825153
17
Reanalysis of exome negative patients with rare disease: a pragmatic workflow for diagnostic applications.
Schobers G, Schieving JH, Yntema HG, et al.
Genome medicine 2022; (14(1)):66 doi:10.1186/s13073-022-01069-z.
PMID: 35710456
18
Periodic Genetic Reanalysis Identifies a Novel De Novo NOTCH1 Variant: A Case Report.
Aydin E, Bulut AS, Yildiz B, et al.
Journal of child neurology 2026; 8830738261422860 doi:10.1177/08830738261422860.
PMID: 41834381

This page explains AMCSS genetics and possible overlapping conditions for informational purposes only and does not constitute medical advice. A clinical geneticist, immunologist, and genetic counselor should interpret your child's results and recurrence risk.